الفهرس 
Design of Experiment
ExperimentalOnly 14 pages are availabe for public view
 |  | from | 199 |  |  |
| | | from | 199 | | |
Abstract
Diabetes mellitus is a serious, chronic disease. When diabetes is not well managed, complications develop that endanger health and threaten life. chronic diabetic wounds such as pressure ulcers are significant long-term complications of both type 1 and type 2 diabetes mellitus and due to chronic injury and high rates of recurrence these wounds reflect a particularly serious complication. It is further underlined by the fact that non-healing diabetic wounds are the major cause of amputations. Currently there is one available pharmacologic agents for accelerating healing in diabetic wounds which is Becaplermin gel, a recombinant human platelet-derived growth factor-BB (rhPDGF-BB). However, an increased cancer risk has been found in patients treated with becaplermin and it is not widely used. There is thus an urgent need for effective pharmacological approaches to control and treat delayed wound healing in diabetic patients. In our study, DFO is used as a pharmacological agent because of its ability to provide a novel therapeutic method for improving healing in chronic diabetic wounds and transfersomes were used as a nanocarrier for DFO. The mechanism depends on the transfersomes ability to enhance the penetration of relatively large hydrophilic drug (DFO) and maintain its release.